Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
CADTH
Record ID 32014000844
English
Authors' recommendations:
At the submitted daily cost of $v.vvvv, the cost of saxagliptin is less than that of sitagliptin ($2.95; 100 mg) but is higher than or equal to that of linagliptin ($2.25 to $2.55; 5 mg). Due to variation in reimbursement prices for DPP-4 across the country, the price of saxagliptin would need to be reduced by at least vvvvvv% (to $2.25) to avoid incurring additional costs to plans that cover linagliptin. If saxagliptin were to replace sitagliptin as the most widely used DPP-4 drug, this would generate substantial cost savings for public plans.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0329_Onglyza_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cost-Benefit Analysis
- Dipeptidyl-Peptidase IV Inhibitors
- Diabetes Mellitus, Type 2
- Incretins
- Hypoglycemic Agents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.